Corcept Therapeutics Incorporated (CORT)
Quantitative Summary
DeterministicCORT trades at 198.5x earnings — a 205% premium to its sector average of 65.2x — without a dominant ROIC-WACC spread. Financial health is average: Piotroski 5/9, Altman Z 16.8.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe capital allocation efficiency for Corcept Therapeutics presents a notable divergence from traditional growth equity norms, characterized by an ROIC of 5.3% that falls short of the 8.0% cost of capital, resulting in a negative spread of -2.7%. Despite this drag on value creation, earnings quality metrics remain robust; the company maintains a high Piotroski F-Score of 5/9 and a solid Altman Z-Score of 16.8, suggesting strong financial stability without signs of manipulation indicated by its Beneish M-Score of -2.81. The profitability profile is driven almost exclusively by operational leverage rather than balance sheet expansion or asset turnover, evidenced by an exceptional gross margin of 98.3% and a net margin of 13.1%, even as revenue expands at a measured pace of 12.8%.
Valuation dynamics reveal significant premium pricing relative to both historical norms and sector peers, with the current P/E ratio standing at 51.3x compared to the healthcare sector average of 37.5x. This multiple implies that market participants are pricing in substantial future growth expectations or a unique risk-adjusted return profile not yet reflected in current cash flows. A discounted cash flow analysis suggests a fair value of $30, indicating that the current market price may be trading above intrinsic worth unless the company can sustainably accelerate revenue compounding to justify the elevated multiple. The disparity between the high-quality earnings metrics and the negative capital efficiency spread creates an analytical tension where superior profit margins coexist with value-destructive return on invested capital.
The risk-reward profile is further complicated by the interplay of these conflicting signals; while the fundamental quality scores indicate a stable operating entity, the inability to generate returns exceeding the cost of capital limits long-term shareholder value accretion absent significant strategic shifts or margin expansion beyond current levels. Investors must weigh whether the premium valuation adequately compensates for this structural inefficiency in capital deployment against the safety provided by strong liquidity and earnings stability metrics.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
Interactive5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.
Sensitivity Matrix
| TG ↓ / WACC → | 6% | 8% | 10% |
|---|---|---|---|
| 2% | $38 | $26 | $19 |
| 3% | $49 | $30 | $21 |
| 4% | $71 | $36 | $24 |
Center = base case. Green = >10% upside, Red = >10% downside vs $71.20.
Pre-computed DCF: WACC=8.0%, terminal growth 3%. Fair value $30 (+0.0%). Not investment advice.
Valuation Context
Price Chart with Moving Averages
Technical Setup
AI GeneratedCorcept Therapeutics Incorporated is currently trading at $60.22, a level that requires contextual analysis against its moving averages to determine the prevailing trend direction and price momentum. Without specific data points for short or long-term moving averages, it remains unclear whether the current valuation sits above these benchmarks, indicating bullish strength, or below them, suggesting potential downward pressure. The absence of this comparative data prevents a definitive assessment of whether the asset is in an established uptrend or downtrend at this precise moment. Regarding short-term momentum, the Relative Strength Index (RSI) status is not provided in the available dataset, leaving the immediate velocity of price movement ambiguous. Typically, RSI values above 70 might signal overbought conditions while readings below 30 could indicate oversold states, but without these figures or a defined trend context regarding moving averages, no conclusion can be drawn about whether momentum is accelerating toward exhaustion or gaining traction from a low base. Consequently, the technical picture for Corcept Therapeutics remains incomplete based solely on the current price of $60.22 and sector classification within Healthcare. Investors must await further data points regarding average comparisons and oscillator readings to form a comprehensive view of market dynamics before making any decisions based on momentum or trend analysis alone.
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XPH or SLYG, the fund manager is mechanically forced to buy or sell CORT shares regardless of Corcept Therapeutics Incorporated's individual fundamentals. We estimate $151M of passive capital is structurally linked to CORT through 8 tracked ETFs. Passive flows have a limited but growing influence on CORT's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in Corcept Therapeutics Incorporated to visualize passive redemption contagion across ETFs and collateral stocks.
If Corcept Therapeutics Incorporated (CORT) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ORGANON + CO (OGN) as the most exposed collateral stock, sharing 2 ETFs with CORT. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 9 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
CORT Ownership Dynamics
Passive funds hold 1 in every 33 CORT shares, reducing daily market volatility.
Corcept Therapeutics Incorporated (CORT) exerts measurable gravity on the passive index market, currently representing 3.2% of the XPH (XPH) and 0.7% of the SLYG (SLYG). Across 10 tracked ETFs, approximately 3M shares (3.0% of float) are held by passive funds and rarely trade on the open market. As passive ownership grows, index inclusion changes may increasingly drive price discovery.
ETFs with Highest CORT Exposure
Float lock-up computed from 10 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
CORT Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for Corcept Therapeutics Incorporated over the past year sits near $36.45 (17% of 252-day volume). The current price of $71.20 trades 95.3% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (17% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
CORT Capital Efficiency
How efficiently does Corcept Therapeutics Incorporated convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
Corcept Therapeutics Incorporated converts 304% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. However, the ROIC-WACC spread is negative (-2.7%), suggesting reinvested capital is destroying shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-05 | 264 | $51.60 | $13,622.4 |
| 2026-05-01 | 99,904 | $46.52 | $4.6M |
| 2026-04-30 | 64 | $46.59 | $2,981.76 |
| 2026-04-23 | 93 | $46.57 | $4,331.01 |
| 2026-04-08 | 19 | $41.69 | $792.11 |
| 2026-04-06 | 53,237 | $42.49 | $2.3M |
| 2026-03-16 | 104 | $32.15 | $3,343.6 |
| 2026-03-13 | 102 | $32.39 | $3,303.78 |
| 2026-03-12 | 684 | $33.74 | $23,078.16 |
| 2026-03-10 | 697 | $33.99 | $23,691.03 |
| 2026-02-26 | 209 | $36.22 | $7,569.98 |
| 2026-02-11 | 1 | $40.97 | $40.97 |
| 2026-02-10 | 12 | $41.31 | $495.72 |
| 2026-02-02 | 2,124 | $39.87 | $84,683.88 |
| 2026-01-02 | 6,245 | $34.80 | $217,326 |
| 2025-12-31 | 10 | $70.20 | $702 |
| 2025-12-29 | 92 | $82.65 | $7,603.8 |
| 2025-12-24 | 1,332 | $81.99 | $109,210.68 |
| 2025-12-23 | 10 | $85.11 | $851.1 |
| 2025-12-17 | 2,301 | $81.12 | $186,657.12 |
| 2025-12-15 | 68 | $87.99 | $5,983.32 |
| 2025-12-10 | 21 | $83.15 | $1,746.15 |
| 2025-12-02 | 1,790 | $79.78 | $142,806.2 |
| 2025-11-24 | 2,000 | $77.29 | $154,580 |
| 2025-11-17 | 1 | $75.54 | $75.54 |
| 2025-11-03 | 256 | $73.47 | $18,808.32 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare CORT to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.